2 résultats
Paclitaxel, carboplatin, and durvalumab in extensive stage small-cell lung cancer (ES-SCLC; IFCT-2203 TAXIO phase II trial): Can we improve the chemotherapy (CT) immunotherapy combination in SCLC?
Auteurs / Authors
Moro Sibilot DL, Baranzelli A, Giroux Leprieur E, Amrane K, Leleu O, Zouak A, Molinier O, Le Treut JH Jr, Souquet PJ, Langlais A, Morin F, Cortot AB, Falchero L.
Journal / Conference
ASCO
Année / Year
2026
PMID / session
Etude IFCT
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer
Auteurs / Authors
Moro-Sibilot D, Falchero L, Ardin C, Zouak A, Molinier O, Romand P, Leleu O, Amrane K, Berndt C, Langlais A, Morin F, Westeel V
Journal / Conference
Respiratory Medicine and Research
Année / Year
2024
PMID / session
Etude IFCT
